

FILE 'CAPLUS' ENTERED AT 16:23:56 ON 19 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:23:56 ON 19 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 16:23:56 ON 19 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (four doses) and (wild type) and (three doses) and mutant and (two doses)
L1 4 (FOUR DOSES) AND (WILD TYPE) AND (THREE DOSES) AND MUTANT AND
(TWO DOSES)

=> l1 and starch
L2 3 L1 AND STARCH

=> d l2 ibib ab 1-3

L2 ANSWER 1 OF 3 USPATFULL

ACCESSION NUMBER: 2003:100088 USPATFULL
TITLE: Treatment methods based on microcompetition for a
limiting GABP complex
INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069199	A1	20030410
APPLICATION INFO.:	US 2002-219334	A1	20020815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Hanan Polansky, 3159 S. Winton Rd., Rochester, NY, 14623		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	14837		

AB Microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor associated with chronic disease such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present methods for the treatment of these chronic diseases. The methods are based on modifying such microcompetition, or the effect of such microcompetition on the cell. For instance, treatment may modify the cellular copy number of the foreign polynucleotide, change the rate of complex formation between GABP and either the foreign polynucleotide or the cellular GABP regulated gene, vary the expression of the cellular GABP regulated gene, or manipulate the activity of the gene product of the cellular GABP regulated gene. The invention also presents methods for treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

L2 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER: 2003:99511 USPATFULL

TITLE: Drug discovery assays based on microcompetition for a limiting GABP complex
INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003068616	A1	20030410
APPLICATION INFO.:	US 2002-223050	A1	20020814 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Hanan Polansky, 3159 S. Winton Rd., Rochester, NY, 14623		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	14981		

AB A recent discovery showed that microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor for some of the major chronic diseases, such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present assays for screening compounds based on their effectiveness in modulating such microcompetition, or the effects of such microcompetition on the cell. The selected compounds can be used in treatment of these chronic diseases. The invention also presents assays for screening compounds that can be used in treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

L2 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER: 2002:55752 USPATFULL
TITLE: Novel plants and processes for obtaining them
INVENTOR(S): Chang, Ming-Tang, Ames, IA, UNITED STATES
Keeling, Peter Lewis, Ames, IA, UNITED STATES
Hauber, Richard, Chicago, IL, UNITED STATES
Friedman, Robert, Hammond, IN, UNITED STATES
Katz, Frances, Crown Point, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032919	A1	20020314
APPLICATION INFO.:	US 2001-881735	A1	20010618 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-765248, filed on 9 Oct 1997, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8th Floor, Arlington, VA, 22201-4714		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	1505		

AB The invention relates to a transgenic or mutated plant having genomic material which alters the normal **starch** synthesis pathway within the plant. More specifically, the present invention relates to a plant having a genotype which creates new forms of **starch** in significant quantity. Particularly, the invention relates to grain having an embryo with a genotype heterozygous for two or more

wild type genes (for example, Aa/Bb) and an endosperm having a genotype heterozygous for such genes (for example, AAa/BBb or AAa/bbB or aaA/BBb or aaA/bbB) and the starch produced therefrom.

=> d l1 not l2
L2 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l1 not l2
L3 1 L1 NOT L2

=> d l3 1 ibib ab

L3 ANSWER 1 OF 1 USPATFULL
ACCESSION NUMBER: 2001:25436 USPATFULL
TITLE: Attenuated **mutants** of salmonella which
constitutively express the Vi antigen
INVENTOR(S): Noriega, Fernando R., Baltimore, MD, United States
Sztein, Marcelo B., Columbia, MD, United States
Levine, Myron M., Columbia, MD, United States
PATENT ASSIGNEE(S): University of Maryland, Baltimore, Baltimore, MD,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6190669	B1	20010220
APPLICATION INFO.:	US 1998-76761		19980513 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn Macpeak & Seas. PLLC		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1873		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Attenuated Salmonella **mutants** which constitutively express the Vi antigen are disclosed, as well as vaccines against typhoid fever containing the same, live vector vaccines containing the same, and DNA-mediated vaccines containing the same.

=> d his

(FILE 'HOME' ENTERED AT 16:23:21 ON 19 APR 2003)

FILE 'CAPLUS, WPIDS, USPATFULL' ENTERED AT 16:23:56 ON 19 APR 2003

L1 4 S (FOUR DOSES) AND (WILD TYPE) AND (THREE DOSES) AND MUTANT
AND
L2 3 L1 AND STARCH
L3 1 S L1 NOT L2

=> (quadruple mutant) and (triple mutant) and (double mutant) and (wild type)
L4 20 (QUADRUPLE MUTANT) AND (TRIPLE MUTANT) AND (DOUBLE MUTANT) AND
(WILD TYPE)

=> l4 and starch
L5 1 L4 AND STARCH

=> d 15 1 ibib ab

L5 ANSWER 1 OF 1 USPATFULL

ACCESSION NUMBER: 2000:164310 USPATFULL
TITLE: Activated mutants of SH2-domain-containing protein
tyrosine phosphatases and methods of use thereof
INVENTOR(S): Neel, Benjamin G., Wayland, MA, United States
O'Reilly, Alana M., Watertown, MA, United States
Shoelson, Steven, Natick, MA, United States
Pluskey, Scott, Allston, MA, United States
PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, Boston, MA,
United States (U.S. corporation)
Joslin Diabetes Center, Boston, MA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6156551		20001205
APPLICATION INFO.:	US 1998-92443		19980605 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Achutamurthy, Ponnathapu		
ASSISTANT EXAMINER:	Fronza, Christian L.		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1,58		
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 32 Drawing Page(s)		
LINE COUNT:	8478		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel mutant SH2 domain containing protein tyrosine phosphatases wherein the phosphatase is partially or constitutively active; and whose ability to regulate biological processes are different from the wildtype protein tyrosine phosphatases.

The invention also relates to methods of use of the novel mutants, for example, in in vitro assays to screen for binding partners and inhibitors of protein tyrosine phosphatases and in the treatment of protein tyrosine phosphatase mediated diseases or conditions.

=> d his

(FILE 'HOME' ENTERED AT 16:23:21 ON 19 APR 2003)

FILE 'CAPLUS, WPIDS, USPATFULL' ENTERED AT 16:23:56 ON 19 APR 2003

L1 4 S (FOUR DOSES) AND (WILD TYPE) AND (THREE DOSES) AND MUTANT
AND
L2 3 L1 AND STARCH
L3 1 S L1 NOT L2
L4 20 (QUADRUPLE MUTANT) AND (TRIPLE MUTANT) AND (DOUBLE MUTANT)
AND
L5 1 L4 AND STARCH

=> logoff y

L Number	Hits	Search Text	DB	Tim stamp
1	0	(4789557.pn. or 4790997.pn. r 4774328.pn. or 4770710.pn. or 4798735.pn. or 4767849.pn. r 4801470.pn. r 4789738.pn. or 4792458.pn. or 5009911.pn.) and mutant and ((four adj doses) or quadruple) and (wild adj type)	USPAT; US-PGPUB; EPO; JP ; DERWENT	2003/04/19 15:13
2	0	(4789557.pn. or 4790997.pn. or 4774328.pn. or 4770710.pn. or 4798735.pn. or 4767849.pn. or 4801470.pn. or 4789738.pn. or 4792458.pn. or 5009911.pn.) and mutant and (wild adj type)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:13
3	9	(4789557.pn. or 4790997.pn. or 4774328.pn. or 4770710.pn. or 4798735.pn. or 4767849.pn. or 4801470.pn. or 4789738.pn. or 4792458.pn. or 5009911.pn.) and mutant	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:14
4	10	(4789557.pn. or 4790997.pn. or 4774328.pn. or 4770710.pn. or 4798735.pn. or 4767849.pn. or 4801470.pn. or 4789738.pn. or 4792458.pn. or 5009911.pn.) and mutant	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:20
5	39	quadruple adj mutant	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:20
6	2	(quadruple adj mutant) and starch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:26
7	3	(four adj doses) with mutant	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:27
8	9	((4789557.pn. or 4790997.pn. or 4774328.pn. or 4770710.pn. or 4798735.pn. or 4767849.pn. or 4801470.pn. or 4789738.pn. or 4792458.pn. or 5009911.pn.) and mutant) and starch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:27
9	1	((four adj doses) with mutant) and starch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:35
10	1	((four adj doses) with mutant) and ((two adj doses) same (wild adj type))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:41
11	1	((four adj d ses) with mutant) and ((two adj d ses) sam (wild adj type))) and ((three adj doses) sam (wild adj type)) and ((three adj doses) same mutant)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:57

12	3	((three adj d ses) same (wild adj typ)) and ((three adj dos s) same mutant) and starch	USPAT; US-PGPUB; EP ; JPO; DERWENT	2003/04/19 15:54
13	1	((three adj doses) same (wild adj type)) and ((three adj doses) same mutant) and ((four adj doses) same mutant) and ((two adj doses) same (wild adj type))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/19 15:57